Van Hulzen Asset Management’s Xeris Biopharma Holdings XERS Stock Holding History

Van Hulzen Asset Management’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154K	Hold	19,382	–	–	0.01%	384
2026 Q1	$112K	Sell	19,382 -1,000	-5%	-$6.63K	0.01%	358
2025 Q4	$160K	Sell	20,382 -1,800	-8%	-$14.2K	0.01%	331
2025 Q3	$181K	Buy	22,182 +5,058	+30%	+$33.6K	0.01%	326
2025 Q2	$80K	Buy	17,124 +848	+5%	+$3.88K	0.01%	320
2025 Q1	$89.4K	Sell	16,276 -1,750	-10%	-$7.06K	0.01%	305
2024 Q4	$61.1K	Hold	18,026	–	–	﹤0.01%	471
2024 Q3	$51K	Hold	18,026	–	–	﹤0.01%	318
2024 Q2	$41K	Hold	18,026	–	–	﹤0.01%	301
2024 Q1	$40K	Hold	18,026	–	–	﹤0.01%	320
2023 Q4	$42K	Hold	18,026	–	–	﹤0.01%	309
2023 Q3	$34K	Hold	18,026	–	–	﹤0.01%	298
2023 Q2	$47K	Sell	18,026 -2,252	-11%	-$5.73K	﹤0.01%	300
2023 Q1	$33K	Buy	+20,278	New	+$25.4K	﹤0.01%	299

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Van Hulzen Asset Management's XERS Position: Q2 2026 in Review

Van Hulzen Asset Management held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 19,382 shares worth $154K. The position accounts for 0.01% of the portfolio, ranked #384.

Van Hulzen Asset Management first reported a position in XERS in Q1 2023 and has held it in 14 quarters since. The position peaked at $181K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Van Hulzen Asset Management held 19,382 shares of Xeris Biopharma Holdings worth $154K as of Q2 2026.
Van Hulzen Asset Management left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
Xeris Biopharma Holdings made up 0.01% of Van Hulzen Asset Management's portfolio in Q2 2026, its #384 holding.
Van Hulzen Asset Management first reported a position in Xeris Biopharma Holdings in Q1 2023 and has held it in 14 quarters since.
Van Hulzen Asset Management's Xeris Biopharma Holdings position peaked at $181K in Q3 2025.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Van Hulzen Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.